Indeed, despite some discrepancies, clinical findings have reported higher resistin levels in BC patients with BMI > 25 compared with the health control group with BMI < 25, proposing this adipokine as a future potential therapeutic target [135,136]. The gene discussed is RETN; the disease is breast cancer.